SkinBioTherapeutics (SBTX) AI Stock Analysis

• Market Cap: £37.20M
• Dividend Yield: N/A
• Average Volume (3M): 872.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.14
• Revenue Growth: 1557.07%
• EPS Growth: 24.70%
• Country: UK
• Employees: 15
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 258,779,450
• 10 Day Avg. Volume: 667,746
• 30 Day Avg. Volume: 872,954
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £16.00
• Price Target Upside: 11.27% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: 16.00p ▲(11.27% Upside)

SkinBioTherapeutics faces significant financial challenges with ongoing losses and cash burn, which heavily influence its stock score. While technical indicators show bearish trends, recent positive corporate events and strategic moves offer potential future benefits. However, until these translate into improved financial performance, the stock's score remains low.

SkinBioTherapeutics Business Overview & Revenue Model

Company Description

SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

How the Company Makes Money

SkinBioTherapeutics makes money through the commercialization of its SkinBiotix® technology, mainly by partnering with established companies in the skincare and dermatology sectors to develop and market products. Revenue streams include licensing agreements, where partners pay for the rights to use SkinBiotix® in their product formulations, and potential royalties from product sales. The company may also engage in direct sales of products developed in-house, expanding its revenue base. Significant partnerships with industry leaders help drive revenue and accelerate product development and market entry.

SkinBioTherapeutics Financial Statement Overview

Summary

SkinBioTherapeutics has shown revenue growth but continues to face significant financial challenges. The company reported substantial net losses and negative cash flows. Despite low debt levels, declining equity and unsustainable financing activities pose risks to financial stability.

Income Statement

The company has shown significant revenue growth, increasing from zero in previous years to £1.2 million in 2024. However, the gross profit margin stands at 56.5%, indicating some level of cost control. Despite this, the net profit margin is negative due to high operating expenses, resulting in a substantial net loss. EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet presents a mixed picture. The debt-to-equity ratio is low at 0.28, indicating limited leverage. However, stockholders' equity has been decreasing over recent years, which is concerning. The equity ratio is 56.9%, suggesting moderate reliance on equity financing. Overall, the company's financial stability shows risk due to declining equity.

Cash Flow

Operating cash flow remains negative, though financing activities have provided cash inflows. The free cash flow is negative, indicating cash burn. The operating cash flow to net income ratio is around 0.95, showing that operational cash flows are still insufficient to cover losses. The company's cash position has been bolstered by financing activities, which is unsustainable long-term.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	1.21M	132.06K	74.76K	0.00	0.00
Gross Profit	683.04K	85.19K	15.91K	-5.05K	-5.10K
EBITDA	-2.72M	-2.96M	-2.95M	-1.49M	-1.61M
Net Income	-2.88M	-2.84M	-2.79M	-1.43M	-1.50M
Balance Sheet
Total Assets	5.22M	2.59M	3.08M	5.73M	2.77M
Cash, Cash Equivalents and Short-Term Investments	800.90K	1.31M	1.80M	4.61M	2.16M
Total Debt	818.74K	100.65K	127.86K	139.85K	0.00
Total Liabilities	2.25M	599.34K	609.61K	519.67K	304.83K
Stockholders Equity	2.97M	1.99M	2.48M	5.22M	2.47M
Cash Flow
Free Cash Flow	-2.92M	-2.81M	-2.77M	-1.67M	-965.80K
Operating Cash Flow	-2.73M	-2.65M	-2.67M	-1.56M	-892.14K
Investing Cash Flow	-2.30M	-165.28K	-96.81K	-112.31K	-73.67K
Financing Cash Flow	4.51M	2.32M	-35.12K	4.12M	0.00

SkinBioTherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 14.38
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SBTX, the sentiment is Negative. The current price of 14.38 is below the 20-day moving average (MA) of 16.16, below the 50-day MA of 16.52, and below the 200-day MA of 18.49, indicating a bearish trend. The MACD of -0.51 indicates Positive momentum. The RSI at 23.89 is Positive, neither overbought nor oversold. The STOCH value of 14.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SBTX.

SkinBioTherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TRX	63 Neutral	£20.66M	―	-2.91%	―	-5.33%	60.20%
Sector *	51 Neutral	$7.46B	-0.16	-46.00%	2.25%	22.82%	-2.28%
SAR	47 Neutral	£26.41M	―	-87.30%	―	―	71.17%
SBTX	40 Underperform	£37.20M	―	-63.28%	―	1557.07%	24.70%

SkinBioTherapeutics Corporate Events

SkinBioTherapeutics Secures UK Distribution Deal with Superdrug

SkinBioTherapeutics has announced an exclusive UK commercial agreement with Superdrug Stores plc for its AxisBiotix™ food supplements, aimed at alleviating inflammatory skin conditions. This partnership is expected to enhance the company’s market presence and distribution capabilities in the UK, potentially benefiting stakeholders by expanding the reach of its innovative skin health solutions.

David Brierwood Increases Stake in SkinBioTherapeutics

David Campbell Brierwood has increased his voting rights in SkinBioTherapeutics PLC to 6.34%, up from a previous position of 5.561%. This acquisition of voting rights signifies a notable shift in shareholder influence, potentially impacting the company’s strategic decisions and stakeholder dynamics.

SkinBioTherapeutics Raises £4.2 Million Through Share Issuance

SkinBioTherapeutics plc has successfully raised approximately £4.2 million through a combination of a Placing, Subscription, and WRAP Retail Offer, issuing a total of 24,704,836 new Ordinary Shares at 17 pence per share. This capital raise will support the company’s operational and strategic initiatives, with the new shares expected to be admitted to trading on AIM by 24 June 2025, thereby increasing the company’s total voting rights and share capital.

SkinBioTherapeutics Launches £0.62m Retail Offer Amid Broader Fundraising Efforts

SkinBioTherapeutics plc has announced a retail offer through the Winterflood Retail Access Platform to raise up to £0.62 million by issuing new ordinary shares. This offer is part of a broader fundraising effort, including a placing and subscription to raise approximately £4.1 million. The initiative aims to strengthen the company’s financial position and expand its operations, with the new shares expected to commence trading on AIM on June 24, 2025. This move underscores the company’s commitment to its retail shareholder base and its strategic growth in the skin health sector.

SkinBioTherapeutics Secures Superdrug Deal and Raises £4.1m

SkinBioTherapeutics has signed an exclusive UK commercial agreement with Superdrug for its AxisBiotix™ products, marking a significant milestone as it enters the national high street market. To support this agreement and future product development, the company has raised £4.1 million through a placing and subscription, with an additional proposed retail offer to existing shareholders. The AxisBiotix-Ps product has also received the US National Psoriasis Foundation’s Seal of Recognition, enhancing its credibility and market potential in the USA.

SkinBioTherapeutics Appoints New Adviser and Broker

SkinBioTherapeutics plc has appointed Singer Capital Markets as its Nominated Adviser and Sole Broker, effective immediately. This strategic move is expected to enhance the company’s operational capabilities and market positioning, potentially benefiting stakeholders through improved advisory and brokerage services.

SkinBioTherapeutics Announces Change in Major Holdings

SkinBioTherapeutics PLC, a company involved in the biotechnology sector, has announced a change in its major holdings. The University of Manchester has reduced its voting rights in the company from 3.42% to 2.93%, as of April 29, 2025. This reduction in voting rights could impact the company’s shareholder dynamics and influence future decisions.

SkinBioTherapeutics Announces Change in Voting Rights Structure

SkinBioTherapeutics PLC has announced a change in the breakdown of its voting rights, with Optibiotix Health plc now holding 7.95% of the voting rights, down from a previous 8.46%. This adjustment in voting rights reflects a shift in stakeholder influence within the company, potentially impacting its strategic decisions and governance.